[HTML][HTML] CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis

JL Wang, WY Su, YW Lin, H Xiong, YX Chen, J Xu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
JL Wang, WY Su, YW Lin, H Xiong, YX Chen, J Xu, JY Fang
Oncotarget, 2017ncbi.nlm.nih.gov
CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the
clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial.
Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature
search was performed using Medline, Embase and Web of Science, and the statistical
analysis was conducted using Stata software. A total of twenty-one studies including 3918
colorectal cancer cases were included. The pooled analysis showed that CD44v6 …
Abstract
CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial. Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature search was performed using Medline, Embase and Web of Science, and the statistical analysis was conducted using Stata software. A total of twenty-one studies including 3918 colorectal cancer cases were included. The pooled analysis showed that CD44v6 overexpression in colorectal cancer was an independent prognostic marker correlating with lower 5-year overall survival rate (OR= 0.78, 95% CI= 0.67-0.91, p= 0.001). CD44v6 overexpression was also associated with more lymph node invasion (OR= 1.48, 95% CI= 1.02-2.15, p= 0.04), and advanced Dukes stage (OR= 2.47, 95% CI= 1.29-4.73, p= 0.01). In addition, while excluding Zolbec's study, CD44v6 overexpression was associated with distance metastasis (OR= 1.65, 95% CI= 1.13-2.40, p= 0.01). Taken together, this meta-analysis suggested that CD44v6 is an efficient prognostic factor in colorectal cancer.
ncbi.nlm.nih.gov